These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2891821)

  • 1. Biodegradable microspheres: polyacryl starch microparticles as a delivery system for the antileishmanial drug, sodium stibogluconate.
    Baillie AJ; Coombs GH; Dolan TF; Hunter CA; Laakso T; Sjöholm I; Stjärnkvist P
    J Pharm Pharmacol; 1987 Oct; 39(10):832-5. PubMed ID: 2891821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vesicular systems (niosomes and liposomes) for delivery of sodium stibogluconate in experimental murine visceral leishmaniasis.
    Hunter CA; Dolan TF; Coombs GH; Baillie AJ
    J Pharm Pharmacol; 1988 Mar; 40(3):161-5. PubMed ID: 2899143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-ionic surfactant vesicles, niosomes, as a delivery system for the anti-leishmanial drug, sodium stibogluconate.
    Baillie AJ; Coombs GH; Dolan TF; Laurie J
    J Pharm Pharmacol; 1986 Jul; 38(7):502-5. PubMed ID: 2875149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacies of vesicular and free sodium stibogluconate formulations against clinical isolates of Leishmania donovani.
    Carter KC; Mullen AB; Sundar S; Kenney RT
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3555-9. PubMed ID: 11709339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Visceral leishmaniasis: drug carrier system characteristics and the ability to clear parasites from the liver, spleen and bone marrow in Leishmania donovani infected BALB/c mice.
    Carter KC; Dolan TF; Alexander J; Baillie AJ; McColgan C
    J Pharm Pharmacol; 1989 Feb; 41(2):87-91. PubMed ID: 2568434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug targeting in Leishmania donovani infections using tuftsin-bearing liposomes as drug vehicles.
    Guru PY; Agrawal AK; Singha UK; Singhal A; Gupta CM
    FEBS Lett; 1989 Mar; 245(1-2):204-8. PubMed ID: 2538359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visceral leishmaniasis in the BALB/c mouse: antimony tissue disposition and parasite suppression after the administration of free stibogluconate.
    Collins M; Carter KC; Baillie AJ
    Ann Trop Med Parasitol; 1992 Feb; 86(1):35-40. PubMed ID: 1319700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Visceral leishmaniasis in the BALB/c mouse: a comparison of the in vivo activity of five non-ionic surfactant vesicle preparations of sodium stibogluconate.
    Williams DM; Carter KC; Baillie AJ
    J Drug Target; 1995; 3(1):1-7. PubMed ID: 7655816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The therapeutic effect of sodium stibogluconate in BALB/c mice infected with Leishmania donovani is organ-dependent.
    Carter KC; Baillie AJ; Alexander J; Dolan TF
    J Pharm Pharmacol; 1988 May; 40(5):370-3. PubMed ID: 2899637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sub-optimal dose of Sodium Antimony Gluconate (SAG)-diperoxovanadate combination clears organ parasites from BALB/c mice infected with antimony resistant Leishmania donovani by expanding antileishmanial T-cell repertoire and increasing IFN-gamma to IL-10 ratio.
    Haldar AK; Banerjee S; Naskar K; Kalita D; Islam NS; Roy S
    Exp Parasitol; 2009 Jun; 122(2):145-54. PubMed ID: 19422069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pentavalent antimony-mannan conjugate therapy of experimental visceral leishmaniasis.
    Roberts WL; Hariprashad J; Rainey PM; Murray HW
    Am J Trop Med Hyg; 1996 Oct; 55(4):444-6. PubMed ID: 8916804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic control of drug-induced recovery from murine visceral leishmaniasis.
    Carter KC; Baillie AJ; Alexander J
    J Pharm Pharmacol; 1993 Sep; 45(9):795-8. PubMed ID: 7903366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visceral leishmaniasis: resistance to reinfection in the liver following chemotherapy in the BALB/c mouse.
    Carter KC; Alexander J; Baillie AJ; Dolan TF
    Exp Parasitol; 1989 May; 68(4):375-81. PubMed ID: 2542078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo and in vitro antileishmanial activity of Bungarus caeruleus snake venom through alteration of immunomodulatory activity.
    Bhattacharya S; Ghosh P; De T; Gomes A; Gomes A; Dungdung SR
    Exp Parasitol; 2013 Sep; 135(1):126-33. PubMed ID: 23830987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cured immune phenotype achieved by treatment of visceral leishmaniasis in the BALB/c mouse with a nonionic surfactant vesicular formulation of sodium stibogluconate does not protect against reinfection.
    Carter KC; Baillie AJ; Mullen AB
    Clin Diagn Lab Immunol; 1999 Jan; 6(1):61-5. PubMed ID: 9874665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antileishmanial efficacy and tolerability of combined treatment with non-ionic surfactant vesicle formulations of sodium stibogluconate and paromomycin in dogs.
    Miret JA; Moreno J; Nieto J; Carter KC; Mullen AB; Ambros L; Rodríguez C; San Andrés MI; González F
    Exp Parasitol; 2021 Jan; 220():108033. PubMed ID: 33166530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experimental visceral leishmaniasis: role of trans-aconitic acid in combined chemotherapy.
    Kar S; Kar K; Bhattacharya PK; Ghosh DK
    Antimicrob Agents Chemother; 1993 Nov; 37(11):2459-65. PubMed ID: 8285634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-administration of glycyrrhizic acid with the antileishmanial drug sodium antimony gluconate (SAG) cures SAG-resistant visceral leishmaniasis.
    Bhattacharjee A; Majumder S; Majumdar SB; Choudhuri SK; Roy S; Majumdar S
    Int J Antimicrob Agents; 2015 Mar; 45(3):268-77. PubMed ID: 25600891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of drug resistance in Trypanosoma cruzi and Leishmania donovani by verapamil.
    Neal RA; van Bueren J; McCoy NG; Iwobi M
    Trans R Soc Trop Med Hyg; 1989; 83(2):197-8. PubMed ID: 2558433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cationic liposomal sodium stibogluconate (SSG), a potent therapeutic tool for treatment of infection by SSG-sensitive and -resistant Leishmania donovani.
    Sinha R; Roychoudhury J; Palit P; Ali N
    Antimicrob Agents Chemother; 2015 Jan; 59(1):344-55. PubMed ID: 25367907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.